John, Katharina <br/><br/>
Baseline caspase activity predicts progression free survival of temsirolimus-treated head neck cancer patients.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  Aug 2015 
 - 1596-602 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2015.05.021  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Biomarkers, Tumor--blood<br/>Carcinoma, Squamous Cell--blood<br/>Caspases--blood<br/>Disease-Free Survival<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Head and Neck Neoplasms--blood<br/>Humans<br/>Male<br/>Middle Aged<br/>Predictive Value of Tests<br/>Protein Kinase Inhibitors--therapeutic use<br/>Sirolimus--analogs & derivatives<br/>Squamous Cell Carcinoma of Head and Neck